
    
      This is an open label, single-arm and multicenter phase II study designed to evaluate
      Objective Response Rate (ORR) of SCT-I10A for Recurrent/ Metastatic Head and Neck Squamous
      cell Carcinoma who progressed on or after platinum-based chemotherapy.
    
  